Immunotherapy and Pharmaceutical Care for Non-small-cell Lung Cancer Complicated with Hyperthyroidism:Report of One Case.
10.3881/j.issn.1000-503X.11245
- Author:
Zhu SHEN
1
;
Guo Wen CAO
1
;
Ji WANG
2
;
Jie PAN
1
;
Ai Ming SHI
1
;
Zhu ZHU
1
Author Information
1. Department of Pharmacy, the Second Affiliated Hospital of Soochow University,Suzhou,Jiangsu 215004,China.
2. Department of Oncology,the Second Affiliated Hospital of Soochow University,Suzhou,Jiangsu 215004,China.
- Publication Type:Journal Article
- Keywords:
hyperthyroidism;
immunotherapy;
non-small cell lung cancer;
pharmaceutical monitoring
- From:
Acta Academiae Medicinae Sinicae
2020;42(1):132-135
- CountryChina
- Language:Chinese
-
Abstract:
Based on our experience in treating one patients with non-small cell lung cancer complicated with hyperthyroidism,the following considerations in immunotherapy and pharmaceutical care are proposed:role of iodine contrast and contrast agent selection in patients with hyperthyroidism;selection of hemostatic agents and assessment of thrombosis risk in patients with hemoptysis caused by tumor invasion of bronchus;influence of glucocorticoid use on the treatment with programmed cell death-1(PD-1)inhibitor and the role of PD-1 inhibitors in patients with a history of hyperthyroidism;education methods for patients refuse to receive opioids.The participation of clinical pharmacists in the Multiple Disciplinary Team and the multi-dimensional pharmaceutical monitoring for patients can improve the safety and rationality of medications.
